The future energy system will be made up of countless new technologies that are actively being developed and scaled by climate and energy startups around the world. Photo via Getty Images

The global energy landscape is undergoing unprecedented challenges, influenced by post-pandemic work trends, geopolitical events like the Ukraine crisis, and the urgent need to reduce carbon emissions.

To achieve net-zero goals by 2050 and address climate change, a significant investment of $5 trillion by 2030 to USD $4.5 trillion by 2050 is required, necessitating a rapid transformation in traditional energy production, distribution, storage, and consumption methods.

High-tech energy and climate startups are pivotal for a robust economy, driving innovation, economic growth, and enhanced productivity. These startups foster healthy competition, attract crucial investments, and contribute significantly to job creation, outpacing larger companies in terms of employment generation. The U.S., a startup leader, generated over 3.7 million new jobs in 2022, showcasing the adaptability of startups to market trends. Globally, India, with the third-largest startup ecosystem, has contributed to the creation of860,000 jobs since the stand-up of Startup India, emphasizing the importance of nurturing startups for sustained economic dynamism and innovation.

The future energy system will be made up of countless new technologies that are actively being developed and scaled by climate and energy startups around the world. These founding teams require access to scaling resources to accelerate and amplify their impact. Human talent, financial investment, demonstration opportunities and physical facilities are scaling resources that often require significant time and capital to build from scratch. This inefficient resource deployment can be particularly pronounced for hard-tech entrepreneurs. Startup community participants are organized around providing entrepreneurs with the needed access to these resources.

"Our mission is to enable hydrogen adoption by solving the key challenges in hydrogen storage and transportation," says Ayrton CEO, Natasha Kostenuk. "With Halliburton's strategic engineering and manufacturing support, we can scale our technology, execute pilot demonstrations and accelerate towards commercialization."

Halliburton Labs, is highlighted for its diverse team and the support it provides to global entrepreneurs in sustainable ventures. The future energy system is envisioned to be composed of numerous new technologies developed and scaled by climate and energy startups worldwide. These startups require access to scaling resources mentioned above, where Halliburton Labs serves as a conduit between established practitioners and startup entrepreneurs, accelerating the latter's impact by providing access to these critical resources.

Infosys launched the Infosys Innovation Fund to invest in entrepreneurial ventures around the world. Their investment philosophy is geared toward supporting innovation and purposeful solutions that are relevant to the strategic priorities of their clients. This differentiates the Infosys Innovation Fund from most other venture capital institutions, in that they have a strong motivation to create long term value for the end users of the technology and to the companies building these solutions.

Infosys actively collaborates with emerging technology startups through its Infosys Innovation Fund. Employing a Desirability, Feasibility, Viability (DFV) framework, Infosys strategically selects startups and offers advantages such as market, financial and technical scale. The Infosys Innovation Fund stands out for its motivation to create long-term value for end users and the companies building innovative solutions. Infosys also operates an incubation center called ‘Infosys Center for Emerging Technology Solutions’ (iCETS), focusing on NextGen services and offerings through collaboration with clients, startup partnerships, university collaborations, and more.

Startups working with Infosys benefit from accessing the company's know-how, market knowledge, and strategic advisors from the consulting arm of business, Infosys Consulting, who are focused on creating business value through technology innovation. The combined expertise guides entrepreneurs from idea to qualification, proof-of-concept, prototype, minimum viable product (MVP), scale, and continuous discovery and delivery.

Open innovation and trusted partnerships in the energy transition era

In the energy transition era, open innovation and trusted partnerships are becoming essential components of amplifying success for startups. Collaborative cultures and trusted partnerships with companies like Infosys and Halliburton Labs are crucial for supporting and scaling startups in this rapidly evolving energy landscape. This shift towards ‘open innovation’ reflects a broader trend in the industry toward collaboration and shared expertise as key drivers for success to accelerate and achieve global energy transition aspirations.

___

Scott Gale is the executive director of Halliburton Labs. Jason Till is partner of Experience Transformation & Innovation at Infosys Consulting. Rima Thakkar is principal - Americas Energy Transition at Infosys Consulting. Laura Sacchi, Mandar Joshi, and Sonali Sakhare of Infosys Consulting contributed to this article.

This article originally ran on EnergyCapital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.